Patents by Inventor Norihito Tokunaga

Norihito Tokunaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20210269420
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Koichiro FUKUDA, Hiromichi SUGIMOTO, Kentaro RIKIMARU, Yoshihiro BANNO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Yoshihide TOMATA, Yuji ISHICHI, Shogo MARUI, Tsuneo ODA, Tohru MIYAZAKI, Yasutaka HOASHI, Yasushi HATTORI, Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20210198240
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: July 1, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo ODA, Yoshiteru ITO, Tohru MIYAZAKI, Kohei TAKEUCHI, Norihito TOKUNAGA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA, Yuichi KAJITA, Yuhei MIYANOHANA, Takahiro SUGIMOTO, Tatsuki KOIKE, Dilhumar UYGHUR
  • Heterocyclic compound and use thereof
    Patent number: 11028048
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: June 8, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Norihito Tokunaga, Alexander Martin Pawliczek, Tsuneo Oda, Tohru Miyazaki, Marilena Pira, Javier Miguelez-Ramos
  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20200385346
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Heterocyclic compound and use thereof
    Patent number: 10807987
    Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 20, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20200247747
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Norihito Tokunaga, Alexander Martin Pawliczek, Tsuneo Oda, Tohru Miyazaki, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto
  • HETEROCYCLIC COMPOUND
    Publication number: 20200231579
    Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 23, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Eiji KIMURA, Masaki OGINO, Yasuhisa KOHARA, Tomoko OHASHI, Tomohiro KAKU, Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20200207734
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20200207715
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei MIYANOHANA, Tatsuki KOIKE, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20200115399
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • Heterocyclic compound and use thereof
    Patent number: 10584097
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: March 10, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • AROMATIC COMPOUND
    Publication number: 20200039957
    Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
    Type: Application
    Filed: March 29, 2018
    Publication date: February 6, 2020
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji MIWATASHI, Yasufumi MIYAMOTO, Koji WATANABE, Yayoi NAKAYAMA, Yuko HITOMI, Jumpei AIDA, Nobuyuki TAKAKURA, Hideki FURUKAWA, Naoyoshi NOGUCHI, Yasuhiro HIRATA, Kazuaki TAKAMI, Norihito TOKUNAGA, Tomohiro OKAWA, Akita SHIBUYA, Shizuo KASAl, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20200017444
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20190300536
    Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO, Satoshi MIKAMI, Masaki SETO, Shinji MORIMOTO, Shinji NAKAMURA, Sachie TAKASHIMA, Masataka MURAKAMI, Masaki DAINI, Makoto KAMATA, Minoru NAKAMURA, Yasufumi WADA, Hiroyuki KAKEI, Kazuaki TAKAMI, Taisuke TAWARAISHI, Jumpei AIDA, Kouichi IWANAGA, Satoshi YAMAMOTO
  • Heterocyclic compound and use thereof
    Patent number: 10428023
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20190263843
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20190040010
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: February 7, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OHYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20190031611
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: February 1, 2017
    Publication date: January 31, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20170226137
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 10, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
  • HETEROCYCLIC COMPOUND
    Publication number: 20170174682
    Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 22, 2017
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masato YOSHIDA, Hiroyuki NAGAMIYA, Yusuke OHBA, Masaki SETO, Takatoshi YOGO, Satoshi SASAKI, Norihito TOKUNAGA, Kazuyoshi ASO